Euroopan unioni - suomi - EMA (European Medicines Agency)

merck sharp & dohme b.v. - tedisolidifosfaatti - soft tissue infections; skin diseases, bacterial - antibacterials for systemic use, , other antibacterials - sivextro is indicated for the treatment of acute bacterial skin and skin structure infections (absssi) in adults and adolescents 12 years of age and older.

Euroopan unioni - suomi - EMA (European Medicines Agency)

vmd n.v. - tulatromysiini - antibacterials for systemic use, macrolides - cattle; pigs; sheep - cattle: treatment and metaphylaxis of bovine respiratory disease (brd) associated with mannheimia haemolytica, pasteurella multocida, histophilus somni and mycoplasma bovis susceptible to tulathromycin. taudin läsnäolo karjassa olisi perustettava ennen metafylaktista hoitoa. treatment of infectious bovine keratoconjunctivitis (ibk) associated with moraxella bovis susceptible to tulathromycin. pigs: treatment and metaphylaxis of swine respiratory disease (srd) associated with actinobacillus pleuropneumoniae, pasteurella multocida, mycoplasma hyopneumoniae, haemophilus parasuis and bordetella bronchiseptica susceptible to tulathromycin. taudin läsnäolo karjassa olisi perustettava ennen metafylaktista hoitoa. the product should only be used if pigs are expected to develop the disease within 2–3 days. lampaat: tarttuvan pododermatiitin (jalkajuhla) alkuvaiheen hoito, johon liittyy virulentti dichelobacter nodosus, joka vaatii systeemistä hoitoa.

Euroopan unioni - suomi - EMA (European Medicines Agency)

pfizer ireland pharmaceuticals - keftaroliinifosamiili - community-acquired infections; skin diseases, infectious; pneumonia - systeemiset bakteerilääkkeet, - zinforo is indicated for the treatment of the following infections in neonates, infants, children, adolescents and adults: , complicated skin and soft tissue infections (cssti), community-acquired pneumonia (cap) , consideration should be given to official guidance on the appropriate use of antibacterial agents.

Euroopan unioni - suomi - EMA (European Medicines Agency)

a. menarini industrie farmaceutiche riunite s.r.l. - delafloxacin meglumiini - yhteisön hankkimat infektiot - systeemiset bakteerilääkkeet, - quofenix is indicated for the treatment of the following infections in adults:acute bacterial skin and skin structure infections (absssi),community-acquired pneumonia (cap), when it is considered inappropriate to use other antibacterial agents that are commonly recommended for the initial treatment of these infections (see sections 4. 4 ja 5. on otettava huomioon viralliset ohjeet antibioottien tarkoituksenmukaisesta käytöstä.

Euroopan unioni - suomi - EMA (European Medicines Agency)

merck sharp & dohme b.v.  - imipenem monohydraatti, cilastatin sodium, relebactam monohydraatti - gram-negatiivinen bakteeri-infektioita - carbapenems, antibacterials for systemic use, - recarbrio is indicated for:- treatment of hospital-acquired pneumonia (hap), including ventilator associated pneumonia (vap), in adults (see sections 4. 4 ja 5. - treatment of bacteraemia that occurs in association with, or is suspected to be associated with hap or vap, in adults. - treatment of infections due to aerobic gram-negative organisms in adults with limited treatment options (see sections 4. 2, 4. 4, ja 5. on otettava huomioon viralliset ohjeet antibioottien tarkoituksenmukaisesta käytöstä.

Euroopan unioni - suomi - EMA (European Medicines Agency)

nabriva therapeutics ireland dac - lefamulin acetate - pneumonia, bacterial; community-acquired infections - systeemiset bakteerilääkkeet, - xenleta is indicated for the treatment of community-acquired pneumonia (cap) in adults when it is considered inappropriate to use antibacterial agents that are commonly recommended for the initial treatment of cap or when these have failed. on otettava huomioon viralliset ohjeet antibioottien tarkoituksenmukaisesta käytöstä.

Euroopan unioni - suomi - EMA (European Medicines Agency)

sfl pharmaceuticals deutschland gmbh - nyxthracis - anthrax - immunoseerumit ja immunoglobuliinit, - obiltoxaximab sfl is indicated in combination with appropriate antibacterial drugs in all age groups for treatment of inhalational anthrax due to bacillus anthracis (see section 5. obiltoxaximab sfl is indicated in all age groups for post-exposure prophylaxis of inhalational anthrax when alternative therapies are not appropriate or are not available (see section 5.

Suomi - suomi - Fimea (Suomen lääkevirasto)

zoetis animal health aps - danofloxacine mesylate - injektioneste, liuos - 25 mg/ml - danofloksasiini

Suomi - suomi - Fimea (Suomen lääkevirasto)

mylan ireland limited mylan ireland limited - linezolidum - infuusioneste, liuos - 2 mg/ml - linetsolidi

Suomi - suomi - Fimea (Suomen lääkevirasto)

dechra regulatory b.v. - prednisolone - tabletti - 5 mg - prednisoloni